Effective March 1, 2021, pediatric nephrologist Nicole van de Kar has been appointed professor of Complement-Mediated Renal Diseases at Radboud university medical center/Radboud University. Nicole van de Kar will be particularly involved in research on the rare kidney diseases hemolytic-uremic syndrome and C3 glomerulopathy.
The research of Professor of Complement-Mediated Renal Diseases Nicole van de Kar focuses on finding an optimal treatment for the two rare kidney diseases hemolytic-uremic syndrome (HUS) and C3-glomerulopathy (C3G). In both pathologies, the complement system is overactive, ultimately leading to kidney damage.
Unraveling disease mechanisms
Nicole van de Kar (1963, Ubach over Worms/Landgraaf) studied Medicine at Radboud University in Nijmegen and received her PhD with honors in 1994 on her thesis ‘Pathogenesis of the Hemolytic Uremic Syndrome in Childhood’. After completing her doctoral program, she continued her training as a pediatrician and then as a pediatric nephrologist. Van de Kar has had a permanent appointment at the Radboudumc Amalia Children's Hospital since 2000, where she does research on HUS and C3G. Her ambition is to unravel the disease mechanisms underlying these diseases, and thus improve the diagnosis and treatment of patients with HUS and C3G.
Expensive drugs, safe and responsible
Partly due to Van de Kar's research, the Radboudumc has been recognized nationally and Europe-wide as a center of expertise for HUS and C3G. It has taken on the task of using expensive orphan drugs for these diseases safely and responsibly. Partly with grants from ZonMw, Van de Kar is committed as a pediatric nephrologist, and now as a professor, to scientific research and the most optimal care for patients with HUS and C3G.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
ZonMw Open Competition Grant for Annemiek van Spriel and Piet Gros15 June 2021
Annemiek van Spriel, theme cancer development and immune defense, together with Piet Gros, Dept. of Chemistry, Utrecht University obtained a ZonMw Open Competition Grant to investigate IL-6 receptor structure and signalling in tumor cells.read more
Human microbiome could shed light on higher morbidity rate in minoritized populations The link between environmental inequities and disease may lie in the gut15 June 2021
A study published in PNAS is the first to explicitly address the gut microbiome as a pathway to understanding how environmental inequities could lead to health disparities.read more
New ultra-high field MRI system available for Radboudumc and Radboud University10 June 2021
Recently, the Hahn institute in Essen has received a new heart: a 20-ton ultra-high-field MRI scanner from Siemens Healthcare with a magnetic field strength of 7 Tesla. The new CE-approved scanner is ready for business, and projects on body and brain imaging are starting up.read more
On the prevalence of cerebral amyloid angiopathy a systematic review and meta-analysis10 June 2021
Published in ‘Alzheimers and Dementia’, researchers at Radboudumc performed a systematic review and meta-analysis on the prevalence of Cerebral Amyloid Angiopathy. They scrutinized and analyzed 170 publications, comprising publications using either a neuroimaging or a neuropathological approach.read more
Retina-on-chip modeling and treating eye diseases in a dish10 June 2021
Alex Garanto, together with Anneke den Hollander and Andries van der Meer (UTwente) have received 1,17M€ to develop a retina-on-chip model to improve our understanding in eye diseases and to develop treatments against them.read more
New method to prevent ovarian cancer increases quality of life8 June 2021
Researchers at Radboudumc have shown that quality of life is better in women with a BRCA1 or BRCA2 mutation after fallopian tube removal with delayed ovarian removal to prevent ovarian cancer.read more